Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

Costanzo, Giovan Giuseppe Di; Casadei-Gardini, Andrea; Marisi, Giorgia; Foschi, Francesco Giuseppe; Scartozzi, Mario; Granata, R.; Faloppi, Luca; Cascinu, Stefano; Silvestris, Nicola; Brunetti, Oronzo; Palmieri, Vincenzo O.; Ercolani, Giorgio; Tortora, Raffaella

doi:10.1007/s11523-017-0522-5

Cited by 25 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median OS of the present analysis was 11.4 months. Similar survival data have been obtained by Di Costanzo et al in an Italian cohort comprising 279 patients with sorafenib-treated advanced HCC with a median OS of 10.8 months [ 23 ] and in another study with 288 HCC patients with a median OS of 13.6 months [ 14 ]. In a recently published cohort from our department, including 1119 patients with HCC treated in an 11-year period, the median survival of all patients was 15.3 months [ 24 ].…”

Section: Discussionsupporting

confidence: 81%

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

et al. 2018

View full text Add to dashboard Cite

BackgroundIn hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality worldwide, the Child-Turcotte-Pugh score (CTP) is one of the most established tools to assess hepatic reserve and determine survival. Serum levels of insulin-like growth factor-1 (IGF-1) are decreased in patients with chronic liver disease or HCC. A modified score combining circulating IGF-1 with the CTP score (IGF-CTP) was recently proposed.MethodsIGF-CTP scoring was evaluated in 216 patients diagnosed with HCC between 2007 and 2017 to assess the predictive value of serum IGF-1 levels for patient risk stratification and overall survival (OS).ResultsLiver cirrhosis was identified in 80.1% of the study cohort, and alcohol-induced liver disease was the most frequent underlying cause of HCC (44.4%). Serum IGF-1 levels were significantly lower in patients with HCC in cirrhosis compared with non-cirrhotic HCC (p < 0.01). A lower serum level of IGF-1 was associated with more advanced stages of liver cirrhosis (p < 0.05) and cancer stages (p < 0.001). Median OS in the cohort was 11.4 months (range 0.5–118.2 months). OS was significantly higher (10.9 vs. 7.9 months; p < 0.05) in patients with a serum IGF-1 level above the median of 43.4 ng/mL. Patient reassignment using IGF-CTP scoring reclassified 35.6% of patients. Through reassignment, stratification regarding OS was comparable to CTP.ConclusionsThis study is the first to investigate IGF-1 and the IGF-CTP classification in a European cohort of HCC patients. Serum IGF-1 correlates with OS in patients with HCC. However, the IGF-CTP classification was not superior compared to CTP score regarding OS.

show abstract

Section: Discussionsupporting

confidence: 81%

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This aetiological non-homogeneity can be attributed to the expected greater frequency of diabetes in patients with metabolic liver disease. In addition, we also reported an increased toxicity in patients treated with insulin, probably related to the most significant response in patients with increased sorafenib toxicity [12,18].…”

Section: Discussionmentioning

confidence: 66%

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

Casadei-Gardini

Faloppi

Matteis

et al. 2017

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The study reported a strong correlation between this classification and disease progression at 3 mo (41.9%, 25.9% and 12.7% of patients in groups 0, 1 and 2, respectively; P = 0.014). These data were subsequently confirmed in the validation cohort[ 24 ]. A recent meta-analysis by Abdel-Rahman et al[ 25 ] revealed an association between specific side-effects (hypertension, HFSR and diarrhea) and patient outcome (HR = 0.38; 95%CI: 0.30-0.48; P < 0.00001).…”

Section: Clinical Parametersmentioning

confidence: 74%

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Marisi

Cucchetti

Ulivi

et al. 2018

WJG

Self Cite

165

117

View full text Add to dashboard Cite

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.

show abstract

Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma

Abstract: We have validated a useful scoring system to predict outcomes in sorafenib-treated HCC patients. This score is easy to calculate and suitable for implementation in daily clinical practice.

Cited by 25 publications

References 49 publications

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Contact Info

Product

Resources

About